Skip to main content
logo
Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
65.85
-0.30 (-0.45%)
At close: Oct 27, 2025, 4:00 PM EDT
65.50
-0.35 (-0.53%)
After-hours: Oct 27, 2025, 6:54 PM EDT

Halozyme Therapeutics Revenue

Halozyme Therapeutics had revenue of $325.72M in the quarter ending June 30, 2025, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.18B, up 34.97% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.

Revenue (ttm)
$1.18B
Revenue Growth
+34.97%
P/S Ratio
6.95
Revenue / Employee
$3,367,634
Employees
350
Market Cap
7.70B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20241.02B186.07M22.44%
Dec 31, 2023829.25M169.14M25.62%
Dec 31, 2022660.12M216.81M48.91%
Dec 31, 2021443.31M175.72M65.67%
Dec 31, 2020267.59M71.60M36.53%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson92.15B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company53.26B
Novo Nordisk49.11B
Revenue Rankings

HALO News

More News